Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Clinical Trial

Official title:

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01746836
• Other study ID #: 2012-0669
• Secondary ID: NCI-2014-0191120
• Status: Recruiting
• Phase: Phase 2
• Start date: January 17, 2013
• Est. completion date: December 31, 2030

Study information

• Verified date: May 2024
• Source: M.D. Anderson Cancer Center
• Contact: Elias Jabbour, MD
• Phone: (713) 792-4764
• Email: ejabbour[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by blocking a protein needed for cell growth.

Description:

Primary Objectives:

• To estimate the proportion of participants with tyrosine kinase inhibitor (TKI)-resistant, chronic phase CML (CP-CML) attaining major cytogenetic response (MCyR) at 6 months of treatment with second line ponatinib therapy.

• To estimate the time to toxicity related to ponatinib for patients with TKI-resistant CP-CML.

Secondary Objectives:

• To estimate the proportion of participants achieving a MCyR, complete cytogenetic response (CCyR), major molecular response (MMR) and complete molecular response (CMR) at 3, 6, 12, 18 and 24 months of treatment with ponatinib after one second generation TKI failure (by resistance).

• To estimate the time to CCyR, MMR, MCyR and CMR for participants treated with ponatinib as second line therapy for CP-CML

• To evaluate the durations of hematologic, cytogenetic and molecular response to ponatinib after one second generation TKI failure.

• To define the time to progression and overall survival for participants with CML in chronic phase treated with ponatinib after one second generation TKI failure.

• To evaluate the toxicity profile of ponatinib in participants with CML in chronic phase after one second generation TKI failure.

• To evaluate the probability of developing ABL mutations for participants with CML in chronic phase treated with ponatinib after one second generation TKI failure.

• To analyze differences in response rates and in prognosis according to pre-treatment mutations and patient characteristics.

• To investigate mechanisms of resistance in patients who develop resistance to ponatinib used as second line therapy for CP-CML.

• To evaluate symptom burden in participants with CP-CML receiving ponatinib.

Exploratory Objectives:

• To investigate the presence of miRNA that may be predictive of outcome

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2030
• Est. primary completion date: December 31, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Philadelphia chromosome (Ph)-positive (by cytogenetics or fluorescent in situ hybridization [FISH]) or breakpoint cluster region (BCR)-ABL-positive (by polymerase chain reaction [PCR]) CML in chronic phase.

• Participants should have demonstrated to have failure to therapy to one FDA-approved second-generation TKI (currently bosutinib, dasatinib, and nilotinib are approved as frontline therapy), defined as per European leukemiaNet (ELN)35 or National Comprehensive Cancer Network (NCCN) recommendations:

• Less than complete hematologic response (CHR) at or beyond 3 months

• No partial cytogenetic response at or beyond 3 months

• BCR-ABL1 = 10% at or beyond 3 months

• BCR-ABL1 = 1% at or beyond 6 months

• Loss of CCyR or development of mutations or other clonal chromosomal abnormalities at any time during TKI treatment

• Age >18 years

• ECOG performance of 0-2.

• Adequate end organ function, defined as the following: total bilirubin =1.5x ULN (unless due to Gilbert syndrome, in which case it should be =3.0x ULN), SGPT =2.5x ULN, creatinine clearance (CrCL) = 30 mL/min (Cockcroft-Gault formula).

• Participants must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.

• Women of pregnancy potential must practice an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized:

• Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.

• Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential OR women who are surgically sterile.

• In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.

• Women and men must continue birth control for the duration of the trial and at least 3 months after the last dose of study drug.

• All WOCBP MUST have a negative pregnancy test prior to first receiving investigational product.

• Participants should have discontinued therapy with bosutinib, dasatinib or nilotinib or other anti-leukemia therapy (except hydroxyurea), at least 48 hours prior to start of study therapy and recovered from any toxicity due to these therapies to at least grade 1. The use of hydroxyurea is allowed immediately prior to study entry.

Exclusion Criteria:

• Prior therapy with other BCR-ABL-targeted TKIs except bosutinib, dasatinib or nilotinib. Participants with T315I mutations are eligible and will be analyzed separately.

• Active NYHA cardiac class 3-4 heart disease

• Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

• Any history of MI, unstable angina, cerebrovascular accident, or TIA

• Any history of peripheral vascular infarction, including visceral infarction

• Any revascularization procedure, including the placement of a stent

• Congestive heart failure (CHF) (New York Heart Association [NYHA] class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment

• History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia

• Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment

• Participants with active, uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders.

• Have uncontrolled hypertension (i.e., >150 and >90 for SBP and DBP, respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the PI.

• Have poorly controlled diabetes defined as HbA1c values of > 7.5%. Participants with preexisting, well-controlled, diabetes are not excluded.

• Pregnant or breast-feeding women are excluded.

• Participants with history of pancreatitis within 1 year of study or history of chronic pancreatitis.

• Participants in accelerated or blast phase, or patients who have ever been documented to be in blast phase CML, are excluded.

The definitions of excluded CML phases are as follows:

1. Blastic phase: presence of 30% blasts or more in the peripheral blood or bone marrow.

2. Accelerated phase CML: presence of any of the following features:

• Peripheral or marrow blasts 15% or more

• Peripheral or marrow basophils 20% or more

• Thrombocytopenia < 100 x 109/L unrelated to therapy

• Documented extramedullary blastic disease outside liver or spleen

3. Clonal evolution defined as the presence of additional chromosomal abnormalities other than the Ph chromosome has been historically been included as a criterion for accelerated phase. However, participants with clonal evolution as the only criterion of accelerated phase have a significantly better prognosis. Thus, participants with clonal evolution and no other criteria for accelerated phase will be eligible for this study, but analyzed separately.

• Participants who have received more than one FDA-approved TKI for CML, or any investigational, non-FDA approved TKI.

Related Conditions & MeSH terms

• Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase
• Philadelphia Chromosome
• Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
• Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Intervention

Other:
• Laboratory Biomarker Analysis
Blood draws.

Drug:
• Ponatinib Hydrochloride
Starting dose: 30 mg by mouth once a day.

Other:
• Quality-of-Life Assessment
Surveys completed.

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MCyR at 6 months (MCyR6)	The method of Kaplan and Meier will be used to estimate the unadjusted distribution of duration of MCyR. An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses. The distribution of MCyR6 will be tabulated and effects of baseline patient covariates on this variable will be assessed by logistic regression.	At 6 months
Primary	Time-to-toxicity defined as any grade 3 or 4 drug-related adverse event that is not responsive to standard therapeutic management and requires permanent treatment discontinuation	Time-to-toxicity will be monitored using the Bayesian method of Thall, et al. The method of Kaplan and Meier will be used to estimate the unadjusted distribution of time to toxicity. An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses.	Up to 30 days post-treatment
Secondary	Duration of MCyR	The method of Kaplan and Meier will be used to estimate the unadjusted distribution of the duration of MCyR. An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses.	Up to 24 months
Secondary	Time to transformation to accelerated phase CML	The method of Kaplan and Meier will be used to estimate the unadjusted distribution of the time to transformation to accelerated phase CML. An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses.	Up to 5 years
Secondary	Time to transformation to blastic phase CML	The method of Kaplan and Meier will be used to estimate the unadjusted distribution of the time to transformation to blastic phase CML. An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses.	Up to 5 years
Secondary	MMR	An appropriate time-to-event regression model will be fit to the event time data to assess the effects of patient covariates on the event time variable, with the particular model determined by preliminary goodness-of-fit analyses. The distribution of MMR will be tabulated and effects of baseline patient covariates on this variable will be assessed by logistic regression.	Up to 24 months

External Links

•   MD Anderson Cancer Center